| __timestamp | Alpine Immune Sciences, Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 12199547 | 15823000 |
| Thursday, January 1, 2015 | 16054000 | 17026000 |
| Friday, January 1, 2016 | 23316000 | 15941000 |
| Sunday, January 1, 2017 | 10626000 | 18938000 |
| Monday, January 1, 2018 | 28970000 | 58124000 |
| Tuesday, January 1, 2019 | 35847000 | 83837000 |
| Wednesday, January 1, 2020 | 27185000 | 35882000 |
| Friday, January 1, 2021 | 58742000 | 64542000 |
| Saturday, January 1, 2022 | 70243000 | 67995000 |
| Sunday, January 1, 2023 | 80904000 | 80118000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Alpine Immune Sciences, Inc. and CymaBay Therapeutics, Inc. have been at the forefront of this race. From 2014 to 2023, Alpine Immune Sciences increased its R&D expenses by over 560%, reaching a peak in 2023. Meanwhile, CymaBay Therapeutics saw a 400% rise in the same period, with a notable spike in 2019. Both companies have shown a consistent upward trend, with Alpine Immune Sciences slightly edging out CymaBay in recent years. This data highlights the fierce competition and dedication to advancing medical breakthroughs, as both companies strive to lead in the biotech sector.
R&D Spending Showdown: AstraZeneca PLC vs CymaBay Therapeutics, Inc.
Comparing Innovation Spending: Sanofi and CymaBay Therapeutics, Inc.
Research and Development Investment: Gilead Sciences, Inc. vs CymaBay Therapeutics, Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alpine Immune Sciences, Inc.
R&D Insights: How Incyte Corporation and Alpine Immune Sciences, Inc. Allocate Funds
R&D Insights: How Exelixis, Inc. and CymaBay Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Alpine Immune Sciences, Inc. and Viking Therapeutics, Inc.
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Alpine Immune Sciences, Inc. vs Viridian Therapeutics, Inc.
R&D Spending Showdown: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
R&D Insights: How CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. Allocate Funds
Analyzing R&D Budgets: CymaBay Therapeutics, Inc. vs MiMedx Group, Inc.